• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure.

作者信息

Pelliccia F, Borghi A, Ruggeri A, Cianfrocca C, Morgagni G L, Bugiardini R

机构信息

Istituto di Patologia Medica, University of Bologna, Italy.

出版信息

Clin Cardiol. 1993 Aug;16(8):607-12. doi: 10.1002/clc.4960160810.

DOI:10.1002/clc.4960160810
PMID:8370193
Abstract

Several causes may affect the efficacy of angiotensin-converting enzyme (ACE) inhibitors in congestive heart failure (CHF). The present study was undertaken to identify what factors might predict benefits in exercise capacity after ACE inhibition in 22 patients with mild to moderate CHF. All patients underwent hemodynamic evaluation before and following an oral dose of quinapril (20 mg). They were then treated daily with 20 mg of quinapril and underwent exercise stress test off-drugs 1 day and 6 months later. Patients were grouped according to their relative changes in vascular resistances after quinapril: Group A (n = 15) showed a greater decrease in pulmonary vascular resistance (PVR) than in systemic vascular resistance (SVR) (% delta PVR/% delta SVR > 1). The opposite occurred in Group B (n = 7). Comparison of pretreatment baseline features revealed that the two groups had similar biochemical and hormonal variables, cardiac index, and SVR. Conversely, Group A patients had higher (p < 0.05) pulmonary artery pressure and PVR compared with Group B patients. Following quinapril, Group A patients showed a greater (p < 0.05) increase in cardiac index than Group B patients, despite a similar reduction in SVR. Accordingly, 1-day drug treatment significantly (p < 0.001) increased exercise duration in Group A (+29%), but not in Group B patients (+7%). Benefits in exercise capacity were still significant (p < 0.001) 6 months later.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Changes in pulmonary hemodynamics predict benefits in exercise capacity after ACE inhibition in patients with mild to moderate congestive heart failure.
Clin Cardiol. 1993 Aug;16(8):607-12. doi: 10.1002/clc.4960160810.
2
Quinapril in chronic heart failure.
Am J Hypertens. 1990 Nov;3(11):283S-287S. doi: 10.1093/ajh/3.11s.283s.
3
Effect of angiotensin converting enzyme inhibition on plasma endothelin in congestive heart failure.
Int J Cardiol. 1994 Mar 1;43(3):299-304. doi: 10.1016/0167-5273(94)90210-0.
4
The hemodynamics effects of ACE inhibitors in the treatment of congestive heart failure.
J Cardiovasc Pharmacol. 1990;15 Suppl 2:S36-40. doi: 10.1097/00005344-199000152-00007.
5
A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure.一项关于喹那普利治疗轻度慢性心力衰竭的多中心、双盲、安慰剂对照试验。
Eur Heart J. 1993 Mar;14(3):403-9. doi: 10.1093/eurheartj/14.3.403.
6
Dose-related effects of ACE inhibition in man: quinapril in patients with moderate congestive heart failure. The Study Group on Neurohormonal Regulation in Congestive Heart Failure: Lausanne, Switzerland; Berlin, Düsseldorf, Munich, Germany.人ACE抑制的剂量相关效应:喹那普利用于中度充血性心力衰竭患者。充血性心力衰竭神经激素调节研究组:瑞士洛桑;德国柏林、杜塞尔多夫、慕尼黑
Eur Heart J. 1994 Dec;15 Suppl D:113-22. doi: 10.1093/eurheartj/15.suppl_d.113.
7
Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.喹那普利。对其在心血管疾病中的药理学和治疗效果的重新评估。
Drugs. 1994 Aug;48(2):227-52. doi: 10.2165/00003495-199448020-00008.
8
The acute haemodynamic effects of quinapril, a new non-sulfhydryl angiotensin converting enzyme inhibitor, in patients with severe congestive cardiac failure.
Eur J Clin Pharmacol. 1986;31(1):9-14. doi: 10.1007/BF00870978.
9
Preliminary hemodynamic report of the efficacy and safety of quinapril in acute and chronic treatment of patients with congestive heart failure.
Angiology. 1989 Apr;40(4 Pt 2):396-404. doi: 10.1177/000331978904000409.
10
Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.喹那普利在健康志愿者、高血压患者及充血性心力衰竭患者中的临床药理学。
Angiology. 1989 Apr;40(4 Pt 2):360-9. doi: 10.1177/000331978904000405.

引用本文的文献

1
Systemic hemodynamics and pediatric lung disease: mechanistic links and therapeutic relevance.系统性血流动力学与儿科肺部疾病:机制关联与治疗相关性。
Am J Physiol Heart Circ Physiol. 2024 Aug 1;327(2):H454-H459. doi: 10.1152/ajpheart.00271.2024. Epub 2024 Jul 5.
2
Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.喹那普利。对其在心血管疾病中的药理学和治疗效果的重新评估。
Drugs. 1994 Aug;48(2):227-52. doi: 10.2165/00003495-199448020-00008.